Predictors of insulin resistance among Hispanic adults infected with or at risk of infection with the human immunodeficiency virus and hepatitis C virus

Journal of Viral Hepatitis

Volumn 15, Issue 12, 2008, Pages 878-887

  Castaneda Sceppa, C ^b,c   Bermudez, O I ^a,b   Wanke, C ^a   Forrester, J E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; HCV; Hispanic; HIV; Insulin resistance; Liver disease; QUICKI

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEPATITIS C; HEPATITIS VIRUS; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INSULIN RESISTANCE; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; TREATMENT DURATION;

ADULT; COHORT STUDIES; FEMALE; HEPATITIS C; HISPANIC AMERICANS; HIV; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 56549127875     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01021.x     Document Type: Article

References (62)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002 34 : 831 837.
2. Therrian M, Ramirez RR. The Hispanic population in the United States: March 2000. Current Population Reports. Washington DC : US Department of Commerce, Bureau of the Census, 2001.
3. Cheung RC, Currie S, Shen H et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005 100 : 2186 2193.
4. Tedaldi EM, Hullsiek KH, Malvestutto CD et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003 36 : 1313 1317.
5. Anderson RN, Smith BL. HIV deaths: leading causes for 2002. National Vital Statistics Report [online serial] 2005 55 (17 1 90. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_17.pdf.
6. Eyster ME, Diamondstone LS, Lien JM et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993 6 : 602 610.
7. Darby SC, Ewart DW, Giangrande PL et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997 350 : 1425 1431.
8. Torre D, Tambini R, Cadario F et al. Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy. Clin Infect Dis 2001 33 : 1579 1585.
9. Allory Y, Charlotte F, Benhamou Y et al. Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. MULTIVIRC group. Human Pathol 2000 31 : 69 74.
10. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001 32 : 492 497.
11. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005 19 : 593 601.
12. Tatsunami S, Taki M, Shirahata A, Mimaya J, Yamada K. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 2004 111 : 181 184.
13. Bonacini M, Groshen MD, Yu MC et al. Chronic hepatitis C in ethnic minority patients evaluated in Los Angeles County. Am J Gastroenterol 2001 96 : 2438 2441.
14. Hoyumpa A, Sharkey F, Page R et al. Greater prevalence of cirrhosis in Hispanics then in Caucasians or African Americans [abstract]. Hepatology 2005 42 (Suppl 1 442.
15. Verma S, Bonacini M, Govindarajan S et al. More advanced hepatic fibrosis in Hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol 2006 101 : 1817 1823.
16. Lepe R, Layden-Almer JE, Layden TJ, Cotler S. Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 2006 13 : 116 120.
17. Cheung RC, Currie S, Shen H et al. Chronic hepatitis C in Latinos: natural history, treatment eligibility, acceptance, and outcomes. Am J Gastroenterol 2005 100 : 2186 2193.
18. Allison ME, Wreghitt T, Plamer CR et al. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994 21 : 1135 1139.
19. Ozyilkan E, Erbas T, Simsek H et al. Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 1994 253 : 283 284.
20. Fraser GM, Harman I, Meller N et al. Diabetes mellitus is associated with hepatitis C but not chronic hepatitis B infection. Isr J Med Sci 1996 32 : 526 530.
21. Caronia S, Taylor K, Pagliaro L et al. Further evidence for an association between non-insulin dependent diabetes mellitus and chronic hepatitis c virus infection. Hepatology 1999 30 : 1059 1063.
22. Mehta SH, Brancati FL, Sulkowski MS et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000 133 : 592 599.
23. Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007 166 : 196 203.
24. Duong M, Petitie JM, Piroth L et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus co-infected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001 27 : 245 250.
25. Howard AA, Yungtai L, Floris-Moore M et al. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007 21 : 633 641.
26. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. Arch Intern Med 2000 160 : 2050 2056.
27. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort on HIV-infected women. J Acquir Immune Defic Syndr 2003 32 : 298 302.
28. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005 165 : 1179 1184.
29. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000 275 : 20251 20254.
30. Noor MA. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep 2007 4 : 126 134.
31. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989 86 : 27 31.
32. El Sadr WM, Mullin CM, Carr A et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large anti-retroviral naive cohort. HIV Med 2005 6 : 114 121.
33. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Body shape changes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998 19 : 307 308.
34. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 12 : F51 F58.
35. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 353 : 2093 2099.
36. Saint-Marc T, Partisani M, Poizot-Martin I et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000 14 : 37 49.
37. Stern MP, Gaskill SP, Hazuda HP, Gardner LI, Haffner SM. Does obesity explain excess prevalence of diabetes among Mexican Americans? Results of the San Antonio Heart Study. Diabetologia 1983 24 : 272 277.
38. Palaniappan LP, Carnethon MR, Fortmann SP. Heterogeneity in the relationship between ethnicity, BMI and fasting insulin. Diabetes Care 2002 25 : 1351 1357.
39. Tull ES, Thurland A. Dyslipidemia and insulin resistance in relation to genetic admixture among Hispanics and non-Hispanic blacks of Caribbean origin. J Natl Med Assoc 2004 96 : 332 340.
40. Bermudez OI, Tucker KL. Total and central obesity among elderly Hispanics and the association with type 2 diabetes. Obes Res 2001 9 : 443 451.
41. Choudhry S, Coyle NE, Tang H et al. Genetics of Asthma in Latino Americans GALA Study. Population stratification confounds genetic association of studies among Latinos. Hum Genet 2006 118 : 652 664.
42. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Survey. JAMA 2002 16 : 356 359.
43. Kotler DP. HIV Infection and lipodystrophy. Prog Cardiovasc Dis 2003 45 : 269 284.
44. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000 85 : 2402 2410.
45. Bastard JP, Robert JJ, Jardel C, Bruckert E, Grimaldi A, Hainque B. Is quantitative insulin sensitivity check index, a fair insulin sensitivity index in humans? Diabetes Metab 2001 27 : 69 70.
46. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002 87 : 144 147.
47. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006 43 : 1317 1325.
48. Shire N, Rao MB, Anderson JA et al. Improving non-invasive discrimination of fibrosis stage in HIV/HCV co-infected patients. Poster presented at 14th Conference on Retroviruses and Opportunistic Infections (CROI 2007), Los Angeles, CA, 2007. February 28, 2007. Available from: http://www. retroconference.org/2007/PDFs/914.pdf.
49. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation presented at the World Health Organization, June 3-5, 1997. Publication WHO/NUT/NCD/98.1. Geneva, Switzerland : World Health Organization.
50. Jones CY, Wilson IB, Greenberg AS et al. Insulin resistance in HIV-infected men and women in the nutrition for healthy living cohort. J Acquir Immune Defic Syndr 2005 40 : 202 211.
51. Brown TT, Li X, Cole SR et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005 19 : 1375 1383.
52. El-Sadr WM, Mullin CM, Carr A et al. HIV Med 2005 6 : 114 121.
53. Soriano V, Puoti M, Garcia-Gasco P et al. Antiretroviral drugs and liver injury. AIDS 2008 22 : 1 13.
54. Delgado-Borego A, Casson D, Schoenfeld D et al. Hepatitis virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 2004 77 : 703 710.
55. Merchante N, Macias J, Ramayo E et al. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C-virus coinfected patients. J Viral Hepat 2006 13 : 449 456.
56. Su AI, Pezacki JP, Wodicka L et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002 99 : 15669 15674.
57. Walli R, Hertfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1 infected patients. AIDS 1998 12 (15 F167 F173.
58. Noor M, Lo J, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001 15 : F11 F118.
59. Lo JC, Kazemi MR, Hsue PY et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005 41 : 1335 1340.
60. Blumer RME, van Vonderen MGA, Sutinen J et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008 22 : 227 236.
61. Meininger G, Hadigan C, Rietschel P, Grinspoon S. Body composition measurements as predictors of glucose and insulin abnormalities in HIV positive men. Am J Clin Nutr 2002 76 : 460 465.
62. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 : 412 419.